Merck & Co., Inc. (MRK), based in Rahway, New Jersey, is a healthcare company. Valued at $264.2 billion by market cap, the ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...

Merck (MRK) stock gains as Wolfe Research upgrades the company to Outperform, while AbbVie (ABBV) falls as the firm ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee manufacturing ...

WALB Investigates Team received the motion filed Oct. 29, 2025, Merck Co. is asking a Georgia court to dismiss a lawsuit tied ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Brisbane-based Vaxxas has appointed David Peacock to lead the push to bring its vaccine patch technology to market.